Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Clin Cardiol ; 2020 Nov 18.
Article in English | MEDLINE | ID: covidwho-1023275
Aging (Albany NY) ; 13(2): 1620-1632, 2021 01 10.
Article in English | MEDLINE | ID: covidwho-1022288


Both lung adenocarcinoma and coronavirus disease 2019 would cause pulmonary inflammation. Angiotensin-converting enzyme 2, the functional receptor of SARS-CoV-2, also plays a key role in lung adenocarcinoma. To study the risk of SARS-CoV-2 infection in lung adenocarcinoma patients, mRNA and microRNA profiles were obtained from The Cancer Genome Atlas and Gene Expression Omnibus followed by bioinformatics analysis. A network which regards angiotensin-converting enzyme 2 as the center was structured. In addition, via immunological analysis to explore the essential mechanism of SARS-CoV-2 susceptibility in lung adenocarcinoma. Compared with normal tissue, angiotensin-converting enzyme 2 was increased in lung adenocarcinoma patients. Furthermore, a total of 7 correlated differently expressed mRNAs (ACE2, CXCL9, MMP12, IL6, AZU1, FCN3, HYAL1 and IRAK3) and 5 correlated differently expressed microRNAs (miR-125b-5p, miR-9-5p, miR-130b-5p, miR-381-3p and miR-421) were screened. Interestingly, the most frequent toll-like receptor signaling pathway was enriched by mRNA (interlukin 6) and miRNA (miR-125b-5p) sets simultaneously. In conclusion, it was assumed that miR-125b-5p-ACE2-IL6 axis could alter the risk of SARS-CoV-2 infection in lung adenocarcinoma patients.

Adenocarcinoma of Lung/virology , /complications , Lung Neoplasms/virology , Transcriptome , Adenocarcinoma of Lung/metabolism , Computational Biology , Humans , Interleukin-6/metabolism , Lung Neoplasms/metabolism , MicroRNAs/metabolism , Risk Factors
Zhonghua wei zhong bing ji jiu yi xue ; 32(8):928-932, 2020.
Article | WHO COVID | ID: covidwho-760964


OBJECTIVE: To describe the characteristics of liver damage in severe coronavirus disease 2019 (COVID-19) patients in Sichuan area and the effect of antiviral drugs on liver function METHODS: The clinical data of severe COVID-19 patients admitted to Chengdu Public Health Clinical Medical Center from January 21 to February 24, 2020 were retrospectively collected, including demographic data, clinical manifestations and liver function changes within 1 week after admission to intensive care unit (ICU) The changes of liver function during the course of disease in severe COVID-19 patients were analyzed and summarized, and group analysis was performed RESULTS: A total of 30 COVID-19 patients with complete clinical data were enrolled The incidence of severe COVID-19 in elderly men was higher (60 0%), with median age of 61 (47, 79) years old, and those aged 80 or above accounted for 23 3% The severe COVID-19 patients mainly presented with respiratory symptoms such as fever (96 7%), cough (80 0%) and dyspnea (66 7%) The alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and prothrombin time (PT) of 30 patients were increased to various degrees within 1 week after ICU admission, and albumin (ALB) was decreased (1) The patients were divided into two groups according to whether to take lopinavir/ritonavir (kaletra) It was shown that the incidence of liver dysfunction in patients taking kaletra was significantly higher than those who did not take kaletra (7-day abnormal rate of ALT was 54% vs 33%, the abnormal rate of AST was 38% vs 33%, the abnormal rate of TBil was 8% vs 0%), but there were no statistical differences (all P > 0 05) (2) The patients were divided into normal dose group (500 mg, twice a day, n = 19) and reduced dose group (250 mg, twice a day, n = 5) according to the dosage of kaletra It was shown that patients taking low-dose kaletra had a smaller effect on liver function within 1 week after ICU admission than those receiving normal dosage, and ALB, TBil in the reduced dose group were significantly lower than those in the normal dose group on the 2nd day after ICU admission [ALB (g/L): 33 3±2 0 vs 37 5±4 0, TBil (mumol/L): 6 3±3 3 vs 11 3±4 8, both P < 0 05] CONCLUSIONS: Severe COVID-19 patients in Sichuan area suffered obvious liver damage in the early course of the disease and have a slower recovery It is important to pay attention to avoid using drugs that can aggravate liver damage while treating the disease If there is no alternative drug, liver protection treatment should be considered appropriately